Product details
Catalog number BNC473017-100
Price for BNC473017-100
Size / count 1x 100 µL
TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4 T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation) . It has been demonstrated to be upregulated on T cells in many cancers and is an immuno-oncology target for therapy. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is BNC473017-100.
TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3017), CF647 conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd02b1061270361e109959/msds/bnc473017-100.pdf.
TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells.
A starting IHC dilution range is listed on the datasheet, but should be optimized for your specific tissue type and staining protocol.
Yes, safety data sheets are available for hazardous or chemically classified products and can be provided on request or downloaded from the product page.
Suitability for Co-IP depends on the specific antibody and is noted under validated applications on the datasheet. If it isn’t listed, contact our technical support team for guidance based on your target and sample type.